Arcus Biosciences Inc. (NASDAQ: RCUS) stock gained 1.54% in the current market trading. Arcus Biosciences is an oncology-focused biopharmaceutical firm utilizing its extensive cross-disciplinary knowledge to find highly differentiated medicines and to build a comprehensive portfolio of innovative combinations addressing substantial unmet needs.
What’s the update?
Arcus Biosciences provided interim results from Arc-7, which is one of the year’s most anticipated phase 2 clinical trials. Patients treated with RCUS’s anti-Tigit antibody, domvanalimab, showed promising clinical activity, according to RCUS.
Arcus’ stock rose on Thursday as a result of RCUS’ positive assessment of the study. However, Arcus, its collaboration associate Gilead Sciences, and some of the biopharmaceutical industry’s biggest players were hurt by the lack of information provided
Arcus Biosciences started Arc-7, a phase 2 clinical trial with 150 lung cancer patients who were randomly assigned to obtain zimberelimab, an innovative PD-1 blocker, as monotherapy or in combination with domvanalimab. A third cohort in the Arc-7 research was randomly assigned to receive a triple combination that included etrumadenant, the company’s investigational adenosine receptor blocker.
Although etrumadenant’s achievement would be good for Arcus, the biotech industry was anxious to examine response rate statistics for the domvanalimab + zimberelimab cohort against the zimberelimab monotherapy group. That’s because a spate of firms selling PD-1 blockers similar to zimberelimab have been experimenting with mixing them with anti-Tigit antibodies in an attempt to broaden their value.
The highly effective cancer treatments currently block the PD-1 pathway, making it more difficult for tumors to stay hidden from the immune system. Unfortunately, most patients do not respond to PD-1 blockade. PD-1 blockers are being marketed by more than a half-dozen firms, and they’ve squandered billions in recent years chasing medicines like domvanalimab, which improve response rates.
Blocking Tigit, in theory, makes it more difficult for tumor cells to close down the immune system when it strikes. Roche (OTC:RHHBY), one of the firm’s most effective cancer drug developers, announced in January that it would invest heavily in tiragolumab which is an anti-Tigit antibody that emerged to nearly double lung cancer response rates in a phase 1 trial when combined with a PD-1 blocker.
Unfortunately, Roche released results in May indicating that it has seemed to benefit only patients with tumors that overexpress PD-L1. This is especially frustrating because they already know that PD-1 blockage with Tecentriq and comparable medicines works quite effectively in this group.